The use of cefepime as a carbapenem-sparing antibiotic for treating uncomplicated acute pyelonephritis caused by extended-spectrum β-lactamase producing Escherichia coli

Infect Dis (Lond). 2018 Mar;50(3):241-244. doi: 10.1080/23744235.2017.1395066. Epub 2017 Oct 31.

Authors

Jin Woong Suh¹, Kyung Sook Yang², Sun Bean Kim¹, Jong Hun Kim¹, Jang Wook Sohn¹, Min Ja Kim¹, Young Kyung Yoon¹

Affiliations

¹ a Department of Internal Medicine, Division of Infectious Diseases , Korea University College of Medicine , Seoul , Republic of Korea.
² b Department of Biostatistics , Korea University College of Medicine , Seoul , Republic of Korea.

PMID: 29086602
DOI: 10.1080/23744235.2017.1395066

No abstract available

Publication types

Comparative Study
Letter

MeSH terms

Aged
Anti-Bacterial Agents / therapeutic use*
Carbapenems / adverse effects
Carbapenems / therapeutic use
Cefepime
Cephalosporins / therapeutic use*
Ertapenem
Escherichia coli / enzymology*
Escherichia coli / isolation & purification
Escherichia coli Infections / drug therapy*
Escherichia coli Infections / microbiology
Female
Hospitals, University
Humans
Male
Middle Aged
Pyelonephritis / diagnosis
Pyelonephritis / drug therapy*
Pyelonephritis / microbiology
Republic of Korea
Retrospective Studies
Risk Factors
Treatment Outcome
beta-Lactamases / metabolism
beta-Lactams / therapeutic use

Substances

Anti-Bacterial Agents
Carbapenems
Cephalosporins
beta-Lactams
Cefepime
beta-Lactamases
Ertapenem